Title Drug Induced Diseases, 3/e
Subtitle Prevention, Detection, and Management
Author James E Tisdale, Douglas A Miller
ISBN 9781585285303
List price USD 225.00
Price outside India Available on Request
Original price
Binding Paperback
No of pages 1400
Book size 153 x 229 mm
Publishing year 2018
Original publisher ASHP - American Society of Health-System Pharmacists (Eurospan Group)
Published in India by .
Exclusive distributors Viva Books Private Limited
Sales territory India, Sri Lanka, Bangladesh, Pakistan, Nepal, .
Status New Arrival
About the book Send Enquiry


Drug-induced diseases are unintended effects of drugs that result in mortality or morbidity with symptoms sufficient to prompt a patient to seek medical attention and/or require hospitalization.
Drug-Induced Diseases provides a detailed overview of diseases that result from drug therapy, arming healthcare professionals with critical knowledge to protect the health and welfare of their patients.

Now in its third edition, this important reference helps healthcare practitioners, residents, and students by expanding the understanding of disease state causes and effects, encouraging critical thinking, and raising awareness that many diseases can be caused or exacerbated by a medication the patient is taking.

The third edition has been revised and expanded, and includes:

  • 58 peer-reviewed chapters authored by 99 contributors
  • Detailed, comprehensive tables
  • New chapters including Bleeding Disorders, Teratogenicity, and Oral Manifestations of Systemically Administered Drugs
  • Comprehensive coverage of scores of drug-induced diseases
  • Information pertaining to the contribution of genetic polymorphisms to specific drug-induced diseases
  • Levels of evidence” classification for identifying the strength of evidence that links a listed drug to a specific drug-induced disease
  • And much more






Section I–Magnitude/Significance of Drug-Induced Diseases: Impact on the Healthcare System

Chapter 1: Drug Safety and Drug–Induced Diseases: The Regulatory, Legal, and Practice Environments (Cynthia Reilly, MS, BS Pharm)

Chapter 2: Epidemiology and Public Health Impact of Drug-Induced Diseases (John R. Litaker, PhD, MSc, MMedSc, and James P. Wilson, PharmD, PhD, FASHP)

Chapter 3: Factors Contributing to Drug–Induced Diseases (Tyler Shugg, PharmD, Abdullah Assiri, PharmD, and Brian R Overholser, PharmD)

Chapter 4: Postmarketing Surveillance for Drug-Induced Diseases (Tobias Peschel, MD, PhD, MBA, and Hugh H. Tilson, MD, DrPH)

Chapter 5: Evaluating Patients for Drug-Induced Diseases (Douglas A. Miller, PharmD, and James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA)


Section II–Drug-Induced Dermatologic Diseases

Chapter 6: Drug Allergy and Cutaneous Diseases (Lynne M. Sylvia, PharmD)

Chapter 7: Systemic Lupus Erythematosus-Like Syndrome (Karen W. Lee, PharmD, BCPS, and Matthew F Ambury, PharmD, BCPS)

Chapter 8: Photosensitivity (Julie M. Koehler, PharmD, FCCP)

Chapter 9: Alopecia, Hirsutism, and Hypertrichosis (Kristine E. Keplar, PharmD)

Section III–Drug-Induced Neurological Diseases

Chapter 10: Seizures (Timothy E. Welty, PharmD, FCCP, BCPS)

Chapter 11: Stroke (Denise H. Rhoney, PharmD, FCCP, FCCM, FNCS)

Chapter 12: Movement Disorders (Jack J. Chen, PharmD, FASCP, FCCP, BCPS, BCGP; Khashayar Dashtipour, MD, PhD; and David M Swope, MD)

Chapter 13: Peripheral Neuropathy (Dennis Parker, Jr. PharmD)

Chapter 14: Visual Disturbances (Yaman Kaakeh, PharmD, BCPS, BCNSP, CNSC, and Steven R. Abel, PharmD, FASHP)

Chapter 15: Delirium (Matthew A. Fuller, PharmD, FASHP, BCPP)

Chapter 16: Sleep Disorders (Lisa L. Forsyth, PharmD, FCCM)

Chapter 17: Cognitive Disorders (Michele Y. Splinter, PharmD, MS, BCPS, FCCP)


Section IV–Drug-Induced Psychiatric Diseases

Chapter 18: Depression (Sheila Botts, PharmD, FCCP, BCPP, and Melody Ryan, Pharm D, MPH)

Chapter 19: Anxiety (Julie A. Dopheide, PharmD, BCPP, FASHP, and Seth Gomez, PharmD, BCPP)

Chapter 20: Psychosis (Jessica L. Goren, PharmD, BCPP)


Section V–Drug-Induced Pulmonary Diseases

Chapter 21: Interstitial Lung Disease/Pulmonary Fibrosis (Jordan R. Covvey, PharmD, PhD, BCPS, and Erin E. Mancl, PharmD, BCPS, BCCCP)

Chapter 22: Asthma and Bronchospasm (Suzanne G. Bollmeier, PharmD, BCPS, AEC, and Rebecca L. Stauffer, PharmD, BCPS)


Section VI–Drug-Induced Cardiovascular Diseases

Chapter 23: Myocardial Ischemia and Acute Coronary Syndromes (Kevin M. Sowinski, PharmD, FCCP)

Chapter 24: Heart Failure (Yazid N. Al Hamarneh BSc(Pharm), PhD, and Ross T Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS)

Chapter 25: Ventricular Arrhythmias (James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA)

Chapter 26: Supraventricular Arrhythmias (James E. Tisdale, PharmD, BCPS, FCCP, FAPhA, FNAP, FAHA)

Chapter 27: Hypertension (Liza W. Claus, PharmD, BCACP, and Joseph J Saseen, PharmD, BCPS, BCACP, FCCP, FASHP)

Chapter 28: Hypotension (Katy E. Trinkley, PharmD, BCACP, and Robert L Page II, PharmD, MSPH, BCPS (AQ-Cardiology), BCGP, FCCP, FAHA, FASHP, FHFSA

Chapter 29: Valvular and Pericardial Heart Disease (Sarah A. Spinper, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ-Cardiology), and Frank E. Silvestry, MD, FACC, FASE)


Section VII–Drug-Induced Endocrine Diseases

Chapter 30: Glucose and Insulin Dysregulation (Devra K. Dang, PharmD, BCPS, CDE, FNAP; Frank Pucino, Jr. PharmD, MPH, FASHP, FCCP; Charles D. Ponte, PharmD, BC-ADM, BCPS, CDE, CPE, FAADE, FAPhA, FASHP, FCCP, FNAP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP )

Chapter 31: Thyroid Diseases (Genevieve Lynn Ness, PharmD; Judy T. Chen, PharmD, BCPS, BCACP, CDE, FNAP; Betty J. Dong, PharmD, FASHP, FAPhA, FCCP; Frank Pucino, Jr, PharmD, MPH, FASHP, FCCP; and Karim Anton Calis, PharmD, MPH, FASHP, FCCP)

Chapter 32: Hypothalamic, Pituitary, and Adrenal Diseases (Andrew Y Hwang, PharmD, BCPS; Steven M. Smith, PharmD, MPH, BCPS; and John G. Gums, PharmD, FCCP)

Chapter 33: Sexual Dysfunction in Males (Mary Lee, PharmD, BCPS, FCCP, and Roohollah Sharifi, MD, FACS)

Chapter 34: Gynecologic Diseases and Infertility in Women  (Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP)


Section VIII–Drug-Induced Gastrointestinal Diseases

Chapter 35: Upper Gastrointestinal Ulceration (Dianne W. May, PharmD, FCCP, BCPS; Micaela Carroll, PharmD, BCPS; and J. Russell May, PharmD, FASHP)

Chapter 36: Diarrhea (Sarah A. Nisly, PharmD, BCPS, FCCP, and Alison M. Walton, PharmD, BCPS)

Chapter 37: Constipation (Sarah A. Nisly, PharmD, BCPS, FCCP, and Carolyn M. Jung, PharmD, BCPS)

Chapter 38: Hepatic and Cholestatic Diseases (Scott S. Malinowski, PharmD, and Daniel M. Riche, PharmD, FCCP, BCPS, CDE, ASH-CHC, CLS)

Chapter 39: Pancreatitis (Pramodini B. Kale-Pradhan, PharmD, and Sheila M. Wilhelm, PharmD, FCCP, BCPS)

Chapter 40: Nausea and Vomiting (Saeed K. Alzghari, MS, MBA (HOM), PharmD BCPS; Bonnie A. Labdi, PharmD, BCOP; and Jon D. Herrington, PharmD, BCPS, BCOP)


Section IX–Drug-Induced Diseases of the Kidney and Fluid & Electrolyte Disorders

Chapter 41: Acute Kidney Injury (Amy Barton Pai, PharmD, BCPS, FASN, FCCP, FNKF, and Nicole M. Wegrzyn, PharmD, BCACP)

Chapter 42: Chronic Kidney Disease (Mary. K Stamatakis, PharmD)

Chapter 43: Syndrome of Inappropriate Antidiuretic Hormone Secretion and Diabetes Insipidus (Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS, and Daniel E. Hilleman, PharmD, FCCP)

Chapter 44: Acid-Base Disorders (Lori D Wazny, BSc(Pharm), PharmD, EPA; Christine Davis, BSc(Pharm), PharmD, ACPR and Robert E. Ariano, PharmD, BCPS, FCCM)


Section X–Drug-Induced Hematological Disorders

Chapter 45: Bleeding Disorders (Tiffany Pon, PharmD, BCPS, and Jaekyu Shin, PharmD, MS, BCPS)

Chapter 46: Thrombocytopenia (kellie Jones Weddle, PharmD, BCOP, FCCP; FHOPA, and Patrick J. Kiel, PharmD, BCPS, BCOP)

Chapter 47: Thromboembolic Diseases (Candice L. Garwood, PharmD, FCCP, BCPS, BCACP)

Chapter 48: Neutropenia and Agranulocytosis (Teresa C. Thakrar, PharmD, BCOP, and Christopher A. Fausel, PharmD, MHA, BCOP)

Chapter 49: Anemias (LeAnn B. Norris, PharmD, BCPS, BCOP, and Charles L. Bennett, MD, PhD, MPP)


Section XI–Drug-Induced Bone, Joint, And Muscle Diseases

Chapter 50: Osteoporosis and Osteomalacia (Laura M. Borgelt, PharmD, FCCP, BCPS, and Danielle R. Fixen, PharmD)

Chapter 51: Gout and Hyperuricemia (Jasmine D. Gonzalvo, PharmD, BCPS, BC-ADM, CDE, LDE)

Chapter 52: Myopathy (Craig Williams, PharmD, FLNA, BCPS)


Section XII–Miscellaneous Drug-Induced Diseases

Chapter 53: Weight Gain (Amy Heck Sheehan, PharmD)

Chapter 54: Temperature Dysregulation (Susan M. Wilson, PharmD, and Ian A Ross, PharmD)

Chapter 55: Ototoxicity (Monica L. Miller, PharmD, MS)

Chapter 56: Oral Manifestations of Systemically Administered Drugs (Ashley H. Meredith, PharmD, BCACP, BCPS, CDE)

Chapter 57: Neoplastic Diseases (Sandra Cuellar, PharmD, BCOP, and Christina Mactal Haaf, PharmD, BCOP, BCPS)

Chapter 58: Teratogenicity (Kylie N. Barnes, PharmD, BCPS)


About the Authors:

James E. Tisdale, PharmD, BCPS, FCCP, FAphA, FNAP, FAHA, Professor, College of Pharmacy, Purdue University, Indiabapolis, Indiana. Adjunct Professor, School of Medicine, Indiana University, Indiabapolis, Indiana.

Douglas A. Miller, PharmD, Professor (Emeritus), College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan.   

Target Audience:

This book is the must-have resource for pharmacists, physicians, nurses, and pharmacy students alike.


Special prices are applicable to the authorised sales territory only.
Prices are subject to change without prior notice.